u/julet0790 · 318d agono track record yet
“holding very large position”
Sellas $sls
Sellas Life Sciences is showing strong Phase 2 data for SLS009 in relapsed blood cancers (46% response rate, 58% in prior-therapy patients, median survival 8.9 months vs. 2.5 months baseline). Upcoming Phase 3 trials in newly diagnosed patients and final GPS Phase 3 results by year-end represent significant catalysts for a potential multi-fold gain.
At post $1.90Now $11.39+499.5% since postedas of Oct 23, 12:00 PM ET
1d+3.2%
3d+6.8%
1w+15.8%
1m+103.2%
3m+213.7%
6m+333.2%
1y—